N
Nucleai
AI-powered spatial biology solutions for precision medicine, enhancing drug response predictions and tissue analysis
About Nucleai
Nucleai.ai operates at the intersection of artificial intelligence and spatial biology, focusing on precision medicine. The company provides AI-powered image analysis applications to pharmaceutical companies and clinicians, aiming to predict drug responses and analyze tissue architecture. Nucleai's algorithms detect and characterize the spatial arrangement of cells, which is crucial for understanding the interactions between the immune system and tumor microenvironment. This technology is particularly valuable in the development of next-generation immunotherapies. Nucleai serves clients in the pharmaceutical and healthcare sectors, primarily targeting those involved in oncology and immunotherapy research. The company operates in the biotech and healthcare markets, leveraging its expertise in AI and pathology to offer unique insights that can drive better clinical outcomes. Nucleai's business model revolves around providing software solutions and analytical services, generating revenue through licensing fees and service contracts. The company collaborates with research institutions and pharmaceutical firms to validate its technology and expand its application scope.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Chicago, United States
- Employees
- 67
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Precision Medicine, Biotech and Pharma, Techbio, Hard Tech, Techbio Drug Discovery, DT and LS, science-based
- Technology
- Deep Tech
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2024 | $14M | $165M | Undisclosed | — |
| SERIES BOther financing | Mar 2022 | $33M | $132M | Undisclosed | — |
Growth signals
Latest recorded traffic for Nucleai is 3.5K monthly website visits, up 45.8% over the last three months. Nucleai's team declined 9.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 ASYLIACompanion Diagnostics For Immunotherapy | Asylia Diagnostics |
Beerse, Belgium | Operational | 7 | $1.2M | $427K |
 Imagene AIAI-based molecular testing for cancer |
Tel Aviv-Yafo, Israel | Operational | |||
 ScailyteDeveloping artificial intelligence technology for the discovery of complex disease patterns from single-cell data |
Basel, Switzerland | Operational | |||
 Arctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics |
Reykjavík, Iceland | Operational | |||
 ChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa |
Glasgow, United Kingdom | Operational | |||
 Protai BioIlluminating the druggable Proteome for better cures |
Tel Aviv-Yafo, Israel | Operational | |||
 QuantHealthAI-powered simulation for clinical trial optimization. |
Tel Aviv-Yafo, Israel | Operational | |||
 MytosInfrastructure for fully automated manufacture of any human cell type |
London, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nucleai on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nucleai’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.